Bispecific Fusion Proteins for Dual Complement and VEGF Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents are inadequate in simultaneously inhibiting the complement and VEGF pathways, which contribute to various diseases with similar etiologies, leading to excessive inflammation and tissue damage.
Innovation Solution
Development of bispecific fusion proteins comprising a complement inhibiting domain (CID), a VEGF inhibiting domain (VID), and a half-life prolonging domain, which inhibit both the complement activation and VEGF signaling pathways, using specific amino acid sequences and structures to enhance efficacy and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate therapeutic agents are used for complement and VEGF pathways, then each pathway can be inhibited individually, but the treatment complexity increases and efficacy is insufficient for diseases involving both pathways
Solution Approach 1:
The patent combines two separate therapeutic functions (complement inhibition and VEGF inhibition) into a single bispecific fusion protein molecule. This merging approach allows simultaneous inhibition of both pathways through one agent, improving therapeutic efficacy for diseases involving both pathways while simplifying the treatment regimen compared to using separate agents
Solution Approach 2:
The bispecific fusion protein is designed to perform multiple functions: it contains a complement inhibiting domain that binds to complement components (such as C3 or C5) and a VEGF inhibiting domain that binds to VEGF or VEGF receptors. This multi-functionality allows a single molecule to address multiple pathological mechanisms simultaneously, resolving the contradiction between efficacy and treatment complexity
2Duration of action of moving object
If therapeutic agents have short half-life, then they can be cleared quickly from the system, but the duration of action is insufficient for sustained inhibition of complement and VEGF pathways
Solution Approach 1:
The patent incorporates a half-life prolonging domain into the fusion protein structure, merging the therapeutic functions with a pharmacokinetic optimization function. This domain typically contains amino acid sequences or structural features that extend the protein's circulation time in the bloodstream, thereby achieving sustained inhibition of both complement and VEGF pathways without requiring frequent administration
3Adaptability or versatility
If fusion proteins are designed with multiple domains, then they can inhibit both complement and VEGF pathways, but the structural complexity and manufacturing difficulty increase
Solution Approach 1:
The bispecific fusion protein is designed with distinct functional domains that can be independently optimized: a complement inhibiting domain, a VEGF inhibiting domain, and a half-life prolonging domain. These segmented domains are connected by flexible linkers that allow each domain to fold and function independently. This segmentation facilitates rational protein design and simplifies manufacturing by allowing modular construction and quality control of each functional unit
Solution Approach 2:
The fusion protein represents a composite molecular structure combining different functional protein domains into a single polypeptide chain. This composite approach allows the integration of diverse biological functions (complement inhibition, VEGF inhibition, extended half-life) while maintaining the protein's stability and manufacturability through careful domain selection and linkage design
Data Source
AI summary
The invention provides bispecific fusion proteins that inhibit activation of complement pathway and vascular endothelial growth factor (VEGF) pathway and methods for using these fusion proteins.